Developer docs
API playgroundTry for free, no card

Search company profiles

Chai Discovery

Full company profile

uuid00000lr

Namestring
Chai Discovery
Legal namestring
Chai Discovery
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Chai Discovery is a private, venture-backed AI biotech founded in 2024 in San Francisco that builds multi-modal generative foundation models to predict and reprogram the interactions between biological molecules. Its core technology stack spans three generations of proprietary models — Chai-1 (multi-modal all-atom structure prediction across proteins, DNA, RNA, small molecules, and covalent modifications, released open-source under Apache 2.0), Chai-2 (zero-shot generative design of antibodies, nanobodies, and miniproteins achieving ~16% antibody binding and ~68% miniprotein wet-lab hit rates), and Chai-3 (next-generation model with doubled antibody-design success rates and multi-specific engineering, delivered via early-access channels). Wet-lab outcomes are independently validated, including Cryo-EM-confirmed sub-angstrom accuracy on full-length monoclonal antibodies designed against challenging GPCR and peptide-MHC targets.

The company monetizes primarily through multi-year strategic licensing agreements with large pharmaceutical companies, including a reported mid-eight-figure annual platform fee from Eli Lilly (signed Jan 2026) and a license with Pfizer (signed Jun 2026) that bundles early Chai-3 access with a custom model trained on the partner's proprietary data. A second tier of revenue comes from commercial subscriptions to Chai-2 via gated access, freemium academic access, and free-trial distribution of its miniprotein design suite to biotechs participating in Eli Lilly's TuneLab program. Go-to-motion is enterprise field sales into pharma R&D leadership; Chai also distributes through the NVIDIA BioNeMo ecosystem.

Short descriptiontext

Chai Discovery builds proprietary AI foundation models (Chai-1, Chai-2, Chai-3) for biomolecular structure prediction and de novo antibody and miniprotein design, serving large pharmaceutical companies via multi-year licensing deals with Eli Lilly and Pfizer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
AI drug discovery, protein design, antibody engineering, molecular structure prediction, biologics design
Industry3 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Pharma licensing agreements
TypeLicensing Royalties
Description

Multi-year strategic license agreements with pharmaceutical companies (Eli Lilly, Pfizer) granting access to foundation models and custom-trained models on the partner's proprietary data; upfront licensing value plus milestone economics.

biospace.com
2Recurring annual platform fees
TypeSubscription Recurring
Description

Multi-year, mid-eight-figure annual platform fees paid by large pharma for biologics design access, embedding the model into partner discovery workflows.

distilinfo.com
3Commercial access subscriptions
TypeSubscription Recurring
Description

Access to Chai-2 for commercial organizations via gated access request, with ongoing commercial relationships supporting research and product development.

chaidiscovery.com
4Co-developed custom AI models
TypeProfessional Services
Description

Revenue from developing purpose-built AI models trained on a partner's proprietary data, delivered as part of broader strategic collaboration packages (e.g., the bespoke model for Lilly, custom model for Pfizer).

financialcontent.com
Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Pricing details5 tiers
1Commercial access to Chai-2
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed; gated by organization access request form for commercial organizations.

chaidiscovery.com
2Academic non-commercial access to Chai-2
ModelFreemiumBilling cadencePay-as-you-go
Notes

Limited non-commercial use for academic researchers via registration of interest.

chaidiscovery.com
3Enterprise pharma platform license
ModelOtherBilling cadenceMulti-year contract
Notes

Multi-year, mid-eight-figure annual fee reported for the Eli Lilly biologics design deal; bespoke custom model and license terms negotiated per partner.

distilinfo.com
4Free trial via Lilly TuneLab
ModelFreemiumBilling cadencePay-as-you-go
Notes

Free trial access to Chai's miniprotein design suite for select TuneLab participating biotechs.

financialcontent.com
5Chai-1 free open access
ModelFreemiumBilling cadencePay-as-you-go
Notes

Free via web interface lab.chaidiscovery.com including for commercial use; model weights and code released under Apache 2.0 license.

chaidiscovery.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Chai Discovery develops multi-modal generative AI foundation models (Chai-1, Chai-2, Chai-3) that predict and reprogram biochemical molecule interactions. The company designs and engineers novel biologics—including monoclonal antibodies, nanobodies, scFvs, miniproteins, and other biomolecules—by predicting structures and generating de novo binders against specified targets. Its platforms serve pharmaceutical and biotechnology partners for drug discovery and biologics design.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Chai Discovery offers a platform of proprietary AI foundation models for molecular design and drug discovery, comprising three generations of models: Chai-1 (multi-modal molecular structure prediction, publicly accessible), Chai-2 (zero-shot de novo antibody and miniprotein design, commercially licensed), and Chai-3 (next-generation model under early access). Chai-1 is distributed to the public via the free Chai Lab Web Interface (lab.chaidiscovery.com) and the open-source chai-lab software library on GitHub under Apache 2.0 license. Chai-2 and its Miniprotein Design Suite are accessed through commercial partnerships (e.g., Eli Lilly, Pfizer, Lilly TuneLab). Together the platform enables scientists to predict, design, and reprogram biomolecular interactions, compressing drug discovery timelines from months or years to weeks.

Product and service7 records
1Chai-1
CategoryCore product
Description

Multi-modal foundation model for molecular structure prediction across proteins, small molecules, DNA, RNA, covalent modifications, and ligands. Achieves state-of-the-art accuracy on drug discovery benchmarks and runs single-sequence mode without MSAs while preserving most performance.

2Chai-2
CategoryCore product
Description

Zero-shot generative platform for fully de novo antibody and miniprotein design, enabling epitope-specific binder generation without high-throughput screening. Achieves double-digit experimental success rates across scFvs, VHH/nanobodies, miniproteins, and full-length mAbs.

3Chai-2 mAb
CategoryProduct extension
Description

Extension of Chai-2 to full-length, drug-like monoclonal antibody design with developability characteristics on par with well-behaved therapeutic antibodies. Validated via Cryo-EM at sub-angstrom accuracy and demonstrated on challenging GPCR and peptide-MHC targets.

4Chai-3
CategoryCore product
Description

Next-generation foundation model that doubles Chai-2's success rate in AI-driven antibody design, enables multi-specific molecule engineering, and reduces antibody design failure rates by half compared to Chai-2. Provided via early-access license to Pfizer.

5chai-lab (open-source library)
CategoryOpen-source library
Description

Open-source software library providing Chai-1 model weights and inference code under Apache 2.0 license, enabling programmatic molecular structure prediction for free commercial and academic use.

6Chai Lab Web Interface
CategoryWeb application
Description

Free web-based interface for running Chai-1 molecular structure prediction, available for commercial applications including drug discovery.

7Miniprotein Design Suite
CategoryProduct module
Description

Chai's miniprotein design suite enabling in-silico molecular candidate generation without traditional library screening. Achieves extremely high success rates (>50%) for miniproteins.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed AI drug discovery company building foundation models for molecular structure prediction and drug design. Most direct competitor to Chai-1/2/3, targeting the same large-pharma licensing model.

TypeDirect peer
Description

AI-driven drug discovery company combining generative chemistry, target identification, and clinical development. Directly comparable AI-native biotech commercializing foundation models to pharma, with broader small-molecule focus but overlapping biologics ambitions.

TypeDirect peer
Description

Flagship Pioneering–backed generative biology company building foundation models (Chroma) to program novel protein therapeutics. Closest direct competitor in generative biologics and antibody/miniprotein design.

TypeDirect peer
Description

AI-driven generative biology company with an integrated wet lab for antibody design. Chai's co-founders include former Absci employees, and the company competes for the same pharma antibody-discovery budgets.

TypeBroad incumbent
Description

Publicly listed AI-driven biotech combining high-throughput wet-lab experimentation with foundation models for target identification and small-molecule discovery. Operates at greater scale and broader scope than Chai, with established pharma partnerships.

TypeDirect peer
Description

AI-native drug discovery company building foundation models (DynamicBPNet) for molecular simulation and protein-ligand interaction prediction. Targets the same pharma licensing and co-development model for AI-designed therapeutics.

TypeDirect peer
Description

AI-driven drug discovery company building physics-based and ML foundation models for small-molecule and protein design. Comparable in stage, capital intensity, and pharma partnership strategy.

TypeEmerging player
Description

AI protein design startup focused on engineering novel protein therapeutics and enzymes. Comparable technology stack and target customer base (biologics-focused pharma), with somewhat narrower scope than Chai's full biomolecule platform.

TypeEmerging player
Description

AI frontier-model company for biology, founded by former Meta FAIR researchers (overlap with Chai's founding team backgrounds). Competes in the foundation-model-for-biology layer that powers Chai-1/2/3.

TypeEmerging player
Description

AI-driven drug discovery startup combining deep generative models with physics-inspired approaches for small-molecule discovery. Chai's co-founders include former Aqemia contributors; comparable in stage and AI-native biotech positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors28 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Chai Discovery

AI Drug Discoverychaidiscovery.com

Chai Discovery builds proprietary AI foundation models (Chai-1, Chai-2, Chai-3) for biomolecular structure prediction and de novo antibody and miniprotein design, serving large pharmaceutical companies via multi-year licensing deals with Eli Lilly and Pfizer.

What Chai Discovery does

Chai Discovery is a private, venture-backed AI biotech founded in 2024 in San Francisco that builds multi-modal generative foundation models to predict and reprogram the interactions between biological molecules. Its core technology stack spans three generations of proprietary models — Chai-1 (multi-modal all-atom structure prediction across proteins, DNA, RNA, small molecules, and covalent modifications, released open-source under Apache 2.0), Chai-2 (zero-shot generative design of antibodies, nanobodies, and miniproteins achieving ~16% antibody binding and ~68% miniprotein wet-lab hit rates), and Chai-3 (next-generation model with doubled antibody-design success rates and multi-specific engineering, delivered via early-access channels). Wet-lab outcomes are independently validated, including Cryo-EM-confirmed sub-angstrom accuracy on full-length monoclonal antibodies designed against challenging GPCR and peptide-MHC targets.

The company monetizes primarily through multi-year strategic licensing agreements with large pharmaceutical companies, including a reported mid-eight-figure annual platform fee from Eli Lilly (signed Jan 2026) and a license with Pfizer (signed Jun 2026) that bundles early Chai-3 access with a custom model trained on the partner's proprietary data. A second tier of revenue comes from commercial subscriptions to Chai-2 via gated access, freemium academic access, and free-trial distribution of its miniprotein design suite to biotechs participating in Eli Lilly's TuneLab program. Go-to-motion is enterprise field sales into pharma R&D leadership; Chai also distributes through the NVIDIA BioNeMo ecosystem.

Chai Discovery firmographics

Firmographics
Name
Chai Discovery
Legal name
Chai Discovery
Website
https://chaidiscovery.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Chai Discovery builds proprietary AI foundation models (Chai-1, Chai-2, Chai-3) for biomolecular structure prediction and de novo antibody and miniprotein design, serving large pharmaceutical companies via multi-year licensing deals with Eli Lilly and Pfizer.
Ownership category
akta.pro rank

Chai Discovery industry classification

Industry
Product category
AI Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • AI drug discovery
  • Protein design
  • Antibody engineering
  • Molecular structure prediction
  • Biologics design

Where Chai Discovery is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Chai Discovery business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Pharma licensing agreements: Multi-year strategic license agreements with pharmaceutical companies (Eli Lilly, Pfizer) granting access to foundation models and custom-trained models on the partner's proprietary data; upfront licensing value plus milestone economics.
  2. Recurring annual platform fees: Multi-year, mid-eight-figure annual platform fees paid by large pharma for biologics design access, embedding the model into partner discovery workflows.
  3. Commercial access subscriptions: Access to Chai-2 for commercial organizations via gated access request, with ongoing commercial relationships supporting research and product development.
  4. Co-developed custom AI models: Revenue from developing purpose-built AI models trained on a partner's proprietary data, delivered as part of broader strategic collaboration packages (e.g., the bespoke model for Lilly, custom model for Pfizer).

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractCommercial access to Chai-2
FreemiumPay-as-you-goAcademic non-commercial access to Chai-2
OtherMulti-year contractEnterprise pharma platform license
FreemiumPay-as-you-goFree trial via Lilly TuneLab
FreemiumPay-as-you-goChai-1 free open access

Go-to-market motion1 record

Chai Discovery product offering

Product offering

Core offering

Chai Discovery develops multi-modal generative AI foundation models (Chai-1, Chai-2, Chai-3) that predict and reprogram biochemical molecule interactions. The company designs and engineers novel biologics—including monoclonal antibodies, nanobodies, scFvs, miniproteins, and other biomolecules—by predicting structures and generating de novo binders against specified targets. Its platforms serve pharmaceutical and biotechnology partners for drug discovery and biologics design.

Product overview

Chai Discovery offers a platform of proprietary AI foundation models for molecular design and drug discovery, comprising three generations of models: Chai-1 (multi-modal molecular structure prediction, publicly accessible), Chai-2 (zero-shot de novo antibody and miniprotein design, commercially licensed), and Chai-3 (next-generation model under early access). Chai-1 is distributed to the public via the free Chai Lab Web Interface (lab.chaidiscovery.com) and the open-source chai-lab software library on GitHub under Apache 2.0 license. Chai-2 and its Miniprotein Design Suite are accessed through commercial partnerships (e.g., Eli Lilly, Pfizer, Lilly TuneLab). Together the platform enables scientists to predict, design, and reprogram biomolecular interactions, compressing drug discovery timelines from months or years to weeks.

Differentiator

Problem solved

Functional benefit

Products and services

  • Chai-1 Multi-modal foundation model for molecular structure prediction across proteins, small molecules, DNA, RNA, covalent modifications, and ligands. Achieves state-of-the-art accuracy on drug discovery benchmarks and runs single-sequence mode without MSAs while preserving most performance.
  • Chai-2 Zero-shot generative platform for fully de novo antibody and miniprotein design, enabling epitope-specific binder generation without high-throughput screening. Achieves double-digit experimental success rates across scFvs, VHH/nanobodies, miniproteins, and full-length mAbs.
  • Chai-2 mAb Extension of Chai-2 to full-length, drug-like monoclonal antibody design with developability characteristics on par with well-behaved therapeutic antibodies. Validated via Cryo-EM at sub-angstrom accuracy and demonstrated on challenging GPCR and peptide-MHC targets.
  • Chai-3 Next-generation foundation model that doubles Chai-2's success rate in AI-driven antibody design, enables multi-specific molecule engineering, and reduces antibody design failure rates by half compared to Chai-2. Provided via early-access license to Pfizer.
  • chai-lab (open-source library) Open-source software library providing Chai-1 model weights and inference code under Apache 2.0 license, enabling programmatic molecular structure prediction for free commercial and academic use.
  • Chai Lab Web Interface Free web-based interface for running Chai-1 molecular structure prediction, available for commercial applications including drug discovery.
  • Miniprotein Design Suite Chai's miniprotein design suite enabling in-silico molecular candidate generation without traditional library screening. Achieves extremely high success rates (>50%) for miniproteins.

Companies that use Chai Discovery

Customer profile

Ideal customer profiles2 records

Chai Discovery technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature5 records

Chai Discovery partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights3 records

Chai Discovery competitors and assessment

Company assessment

Direct peers

  • Isomorphic Labs: Alphabet-backed AI drug discovery company building foundation models for molecular structure prediction and drug design. Most direct competitor to Chai-1/2/3, targeting the same large-pharma licensing model.
  • Insilico Medicine: AI-driven drug discovery company combining generative chemistry, target identification, and clinical development. Directly comparable AI-native biotech commercializing foundation models to pharma, with broader small-molecule focus but overlapping biologics ambitions.
  • Generate Biomedicines: Flagship Pioneering–backed generative biology company building foundation models (Chroma) to program novel protein therapeutics. Closest direct competitor in generative biologics and antibody/miniprotein design.
  • Absci: AI-driven generative biology company with an integrated wet lab for antibody design. Chai's co-founders include former Absci employees, and the company competes for the same pharma antibody-discovery budgets.
  • Genesis Therapeutics: AI-native drug discovery company building foundation models (DynamicBPNet) for molecular simulation and protein-ligand interaction prediction. Targets the same pharma licensing and co-development model for AI-designed therapeutics.
  • Iambic (formerly Entos): AI-driven drug discovery company building physics-based and ML foundation models for small-molecule and protein design. Comparable in stage, capital intensity, and pharma partnership strategy.

Broad incumbents

  • Recursion Pharmaceuticals: Publicly listed AI-driven biotech combining high-throughput wet-lab experimentation with foundation models for target identification and small-molecule discovery. Operates at greater scale and broader scope than Chai, with established pharma partnerships.

Emerging players

  • Cradle Bio: AI protein design startup focused on engineering novel protein therapeutics and enzymes. Comparable technology stack and target customer base (biologics-focused pharma), with somewhat narrower scope than Chai's full biomolecule platform.
  • EvolutionaryScale: AI frontier-model company for biology, founded by former Meta FAIR researchers (overlap with Chai's founding team backgrounds). Competes in the foundation-model-for-biology layer that powers Chai-1/2/3.
  • Aqemia: AI-driven drug discovery startup combining deep generative models with physics-inspired approaches for small-molecule discovery. Chai's co-founders include former Aqemia contributors; comparable in stage and AI-native biotech positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Chai Discovery social profiles

Digital presence

Chai Discovery financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Chai Discovery leadership team

Management profile

Number of profiles

Profiles7 records

Chai Discovery funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors28 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Chai Discovery M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chai Discovery

What does Chai Discovery do?

Chai Discovery develops multi-modal generative AI foundation models (Chai-1, Chai-2, Chai-3) that predict and reprogram biochemical molecule interactions. The company designs and engineers novel biologics—including monoclonal antibodies, nanobodies, scFvs, miniproteins, and other biomolecules—by predicting structures and generating de novo binders against specified targets. Its platforms serve pharmaceutical and biotechnology partners for drug discovery and biologics design.

Is Chai Discovery a public or private company?

Chai Discovery is a private company. It is classified as venture growth investor backed and is currently operating.

When was Chai Discovery founded?

Chai Discovery was founded in 2024. It employs 11 to 50 people.

Where is Chai Discovery based?

Chai Discovery is headquartered in San Francisco, United States, in the North America region.

How does Chai Discovery make money?

Four revenue lines are on record. Pharma licensing agreements are the primary driver. The others are recurring annual platform fees, commercial access subscriptions and co-developed custom AI models.

Who are Chai Discovery's main competitors?

Direct peers on record are Isomorphic Labs, Insilico Medicine, Generate Biomedicines, Absci, Genesis Therapeutics and Iambic (formerly Entos). Recursion Pharmaceuticals is listed as a broad incumbent. Emerging players are Cradle Bio, EvolutionaryScale and Aqemia.

Does Chai Discovery have an API?

Yes. Chai-1 is publicly distributed as an open-source software library (chai-lab) under Apache 2.0 license, providing model weights and inference code hosted on GitHub at github.com/chaidiscovery/chai-lab, and also as a free web interface at lab.chaidiscovery.com available for commercial applications such as drug discovery. Developers can run molecular structure predictions programmatically using the library. Developer documentation is at github.com/chaidiscovery/chai-lab.

What industry is Chai Discovery in?

Chai Discovery's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScienmagAI Expands Understudied Protein Structural Modeling but Encounters CriticalA review of AI protein modeling from 2018-2025 assesses advances in predicting understudied protein structures, covering AlphaFold3, Boltz-1, and Chai-1. It reports AlphaFold3's 76% success rate in protein-ligand pose prediction but notes performance drops to 40-60% on challenging multimers and hallucinations in disordered regions. The authors propose a five-tiered roadmap for validation and consensus modeling.Hartford Business JournalNew Haven Oncology summit highlights AI advances, investment opportunitiesThe Future of Oncology Summit in New Haven highlighted AI's role in cancer research and investment opportunities. Clifford Hudis predicted AI will be integrated into medical practice within five to 10 years, while Annie Lamont noted AI drug-discovery firms like Chai Discovery have generated $100 million in revenue. The summit attracted over 550 registrants and featured 70+ speakers.The Pharma LetterChai Discovery collaborates with Roche in AI-driven drug discoveryChai Discovery announced a collaboration with Roche to use its AI models and platform in drug discovery programs across Roche's therapeutic areas. CEO Joshua Meier said the partnership expands the range of therapeutic programs that can benefit from AI-driven molecular design.Digital Health NewsRoche Partners with Chai Discovery to Leverage AI Models in Drug Discovery ProgrammesRoche partnered with Chai Discovery to integrate its AI models into drug discovery programmes across therapeutic areas. The collaboration uses Chai-3, an AI model for protein-based therapeutics, and follows a similar partnership with Bristol Myers Squibb.HIT ConsultantRoche Partners with Chai Discovery to Deploy Chai-3 Across Global Therapeutic PipelinesRoche partnered with Chai Discovery to integrate Chai-3, an AI molecular engineering platform, into its therapeutic discovery pipelines. The collaboration aims to accelerate lead optimization by generating novel binders for difficult targets. The partnership establishes enterprise integration moats for Chai Discovery.Business Wire BlogChai Discovery Announces Collaboration with Roche in AI-Driven Drug DiscoveryChai Discovery announced a collaboration with Roche to use its AI models in drug discovery programs. Chai-3, the company's latest model, achieves high target success rates and binding affinities. The collaboration is the latest in a series of partnerships with leading pharmaceutical companies in 2026.The Pharma LetterGSK expands work with AI molecule designer Chai DiscoveryGSK announced a collaboration with AI molecule designer Chai Discovery after its laboratory testing found binders to every target. Under the deal, GSK will access Chai's platform, including protein folding and design models, to support discovery work across its pipeline. The evaluation used Chai's models to generate designs against GSK targets zero-shot, without target-specific training.FinancialContent Business PageChai Discovery Announces Collaboration with GSK Following Successful Wet-Lab EvaluationChai Discovery announced a collaboration with GSK after a successful wet-lab evaluation. GSK's designs generated by Chai's models bound to all tested targets, leading to expanded partnership. The collaboration is the latest in a series of partnerships since 2026.FierceBiotechGSK drinks in Chai Discovery’s AI models after wet-lab validationGSK signed up to access Chai Discovery's AI protein-folding and design models after wet-lab validation. Chai's second model achieved a 16% hit rate in de novo antibody design, and GSK's internal testing found binders to all tested targets. Chai's latest model, Chai-3, aims to improve target success rates and binding affinities.Business Wire BlogChai Discovery Announces Collaboration with GSK Following Successful Wet-Lab EvaluationChai Discovery announced a collaboration with GSK after GSK's wet-lab testing of its AI-generated molecular designs found binders to all tested targets. The partnership gives GSK access to Chai's protein folding and design models to power discovery across its pipeline. Chai Discovery is building AI models to accelerate pre-clinical drug discovery.